E-cigarette use is linked to increased risk of COPD and possibly hypertension, though less harmful than traditional smoking, ...

The following is a summary of “Right atrial reservoir strain as an early predictor of pulmonary hypertension development in ...

Tenax Therapeutics progresses levosimendan for PH-HFpEF with Phase 3 trials, aiming for a first-of-its-kind therapy. Click ...

The PAH Initiative is hosting a video event in May to provide information about exercise benefits for PAH patients.

Sotatercept-csrk reduced the risk of major morbidity and mortality events in adults with WHO Group 1 PAH FC 3 or 4 at high risk of mortality.

Pulmonary arterial hypertension (PAH) is a rare and severe lung disease with a life-threatening prognosis. After several positive trials, a recent study has confirmed the efficacy of a biotherapy, ...

A retrospective analysis from Israel suggested that markers of poor hydration are linked to increased risks of hypertension ...

Title : Hemodynamic effects of TX45 , a long-acting Fc-relaxin fusion, in Group 2 pulmonary hypertension patients. Session : Late-breaking science in heart failure, cardiomyopathies, pulmonary ...

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company innovating small molecule kinase inhibitor therapeutics to treat pulmonary arterial ...

Mar. 27, 2025 — A research team has investigated structural changes in kidneys of patients with hypertension and type 2 diabetes. The results show that high blood pressure can lead to ...

Keros Therapeutics halted phase 2 of TROPOS, but KER-065 shows promise in DMD and financial stability ensures growth ...

Pulmonary artery denervation (PADN) may help lower high blood pressure in pulmonary hypertension, a meta-analysis of studies ...